Recombinant oncolytic vaccinia virus and application thereof

The invention relates to a recombinant vaccinia virus, application of the recombinant vaccinia virus in preparation of drugs for treating human cancers and a pharmaceutical composition containing the virus. The recombinant vaccinia virus is obtained by inserting a TGF-beta RII gene segment into a thymidine kinase (TK) gene of a Lister vaccinia virus strain and inserting a GM-CSF gene into a vaccinia virus growth factor (VGF) gene, and the insertion enables the thymidine kinase (TK) gene and the vaccinia virus growth factor (VGF) gene to be inactivated. And the TGF-beta RII gene segment comprises a sequence for coding a TGF-beta binding structural domain of TGF-beta RII. 本发明涉及一种重组痘苗病毒、其在制备治疗人类癌症的药物中的应用以及包含该病毒的药物组合物。所述重组痘苗病毒通过在Lister痘苗病毒毒株的胸苷激酶(TK)基因中插入TGF-βRII基因片段、并在痘苗病毒生长因子(VGF)基因中插入GM-CSF基因而获得，其中，所述插入使得所述胸苷激酶(TK)基因和所述痘苗病毒生长因子(VGF)基因均失活，且所述TGF-βRII基因片段包含编码TGF-βRII的TGF-β结合结构域的序列。